CryoPort Inc (CYRX) Expected to Post Earnings of -$0.09 Per Share

Equities research analysts expect CryoPort Inc (NASDAQ:CYRX) to post ($0.09) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for CryoPort’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.08). CryoPort reported earnings per share of ($0.10) in the same quarter last year, which would suggest a positive year over year growth rate of 10%. The company is scheduled to report its next quarterly earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that CryoPort will report full year earnings of ($0.25) per share for the current financial year, with EPS estimates ranging from ($0.29) to ($0.18). For the next year, analysts forecast that the firm will post earnings of $0.01 per share, with EPS estimates ranging from ($0.11) to $0.26. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover CryoPort.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 6th. The consumer goods maker reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). CryoPort had a negative return on equity of 47.36% and a negative net margin of 66.09%. The firm had revenue of $3.33 million during the quarter, compared to analyst estimates of $3.37 million. The firm’s quarterly revenue was up 49.5% on a year-over-year basis.

Several research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price (up from $10.00) on shares of CryoPort in a research report on Thursday. Roth Capital assumed coverage on CryoPort in a research report on Thursday, November 30th. They issued a “buy” rating and a $12.50 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. CryoPort presently has a consensus rating of “Buy” and a consensus price target of $33.70.

Shares of CryoPort (CYRX) traded down $0.14 during mid-day trading on Monday, reaching $9.83. The company’s stock had a trading volume of 349,955 shares, compared to its average volume of 121,809. CryoPort has a 12 month low of $1.96 and a 12 month high of $10.40. The firm has a market cap of $272.58, a price-to-earnings ratio of -28.09 and a beta of 0.71.

Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CryoPort during the 3rd quarter valued at about $118,000. Bank of Montreal Can acquired a new position in shares of CryoPort during the 4th quarter valued at about $142,000. Goldman Sachs Group Inc. acquired a new position in shares of CryoPort during the 4th quarter valued at about $155,000. Northern Trust Corp increased its holdings in shares of CryoPort by 105.0% during the 2nd quarter. Northern Trust Corp now owns 22,179 shares of the consumer goods maker’s stock valued at $109,000 after acquiring an additional 11,358 shares during the last quarter. Finally, Monashee Investment Management LLC acquired a new position in shares of CryoPort during the 4th quarter valued at about $192,000. 22.83% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at

CryoPort Company Profile

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Get a free copy of the Zacks research report on CryoPort (CYRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with's FREE daily email newsletter.

Leave a Reply